This morning in a courthouse in the southern city of Changsha China, the judge ordered GlaxoSmithKline (ADR) (NYSE: GSK) to pay a $489 million fine for paying bribes to doctors to use their drugs. This record setting fine wasn’t the only punishment given to the British drug maker; jail sentences and deportation were also handed out to executive members of the company.

Mark Reilly, the former head of GSK in China and four other executives were given jail time, each between 2-4 years. Mark Briton Reilly, a former GSK China Manager, is set be deported. The verdict was handed in a rare one-day trial. Chinese regulators are pleased with the verdict; they are increasing their efforts to tackle corporate bribery and malpractice.

Though GSK lost key members, the Chinese government did not ban the company from doing business in China, which is a positive because the Chinese pharmaceutical market is estimated to hit the trillions by 2022.

Xinhua, Chinese news covered the case and had some words in regards to the verdict “If GSK China can learn a profound lesson and carry out its business according to the rule of law, then it can once again win the trust of China’s government and people.”

Though the fine set a record high, it equals 4% of GSK’s 203 operating profit which is less than they expected. GSK said it would pay the fine from cash resources; GSK wanted to reassure those who follow the company by saying that they are still committed to the Chinese health industry. They said that they wanted to be a model company for Chinas emerging health industry.